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Abstract: Contrast-induced acute kidney injury (CI-AKI) is a problem associated with the 
use of iodinated contrast media, causing kidney dysfunction in patients with preexisting renal 
failure. It accounts for 12% of all hospital-acquired kidney failure and increases the length of 
hospitalization, a situation that is worsening with increasing numbers of patients with comorbidi-
ties, including those requiring cardiovascular interventional procedures. So far, its diagnosis has 
relied upon the rise in creatinine levels, which is a late marker of kidney damage and is believed 
to be inadequate. Therefore, there is an urgent need for biomarkers that can detect CI-AKI sooner 
and more reliably. In recent years, many new biomarkers have been characterized for AKI, and 
these are discussed particularly with their use in known CI-AKI models and studies and include 
neutrophil gelatinase-associated lipocalin, cystatin C (Cys-C), kidney injury molecule-1, inter-
leukin-18, N-acetyl-β-d-glucosaminidase, and L-type fatty acid-binding protein (L-FABP). The 
potential of miRNA and metabolomic technology is also mentioned. Early detection of CI-AKI 
may lead to early intervention and therefore improve patient outcome, and in future any one or 
a combination of several of these markers together with development in technology for their 
analysis may prove effective in this respect.
Keywords: radiocontrast media, acute renal failure, markers, renal injury
Introduction
Acute kidney injury (AKI) induced by contrast – known as contrast-induced AKI 
(CI-AKI) or contrast-induced nephropathy (CIN) – is defined as a renal impairment 
occurring 24–72 hours after the intravascular injection of radiographic contrast media 
(CM) in the absence of an alternative etiology. It is usually a nonoliguric, asymptom-
atic, and transient decline in renal function, generally occurring within 24 hours of 
contrast administration, usually peaking on the third to the fifth day and returning to 
the baseline within 10–14 days.
The incidence of AKI has risen in the last decade, likely as a reflection of aging 
populations, which has led to an increase in multiple comorbidities, such as infection-
related hospitalization, and increase in use of nephrotoxic drugs, such as aminoglyco-
sides, nonsteroidal anti-inflammatory drugs, chemotherapeutic drugs, and intravenous 
(IV) contrast agents.1 The use of CM has risen in recent years due to an increase in 
radiographic procedures, and this coupled with an aging population already suffering 
from diabetes and cardiovascular/renal diseases (including chronic kidney disease, 
hypertension, hypotension, advanced congestive heart failure, and compromised left 
ventricular performance) has led to an increase in the incidence of CI-AKI.2–8  CI-AKI 
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is a common cause of hospital-acquired kidney failure, 
accounting for 12% of all cases.9,10
Pathophysiology of CI-AKI
The effects of CM that lead to AKI are not fully understood, 
although two main mechanisms, direct cellular toxicity 
and effects on renal hemodynamics, are believed to be 
involved.11–14 The direct toxic effects of CM have been stud-
ied in various cells, including renal epithelial and mesangial 
cells.15 The functional and structural changes observed as a 
result of CM action included cell death, a decrease in cell via-
bility, and an increase in brush border and lysosomal enzyme 
activity;16 cellular DNA fragmentation;17 downregulation of 
signaling molecules involved in cell survival such as Akt and 
upregulation of signaling molecules in cell death such as the 
p38 and c-Jun N-terminal kinase members of the mitogen-
activated protein kinases and the transcription factor nuclear 
factor kB as well as caspase activation.13,18,19 Nuclear factor 
kB and c-Jun N-terminal kinases are believed to be involved 
in the upregulation of the proinflammatory cytokine interleu-
kin-8 (IL-8).14 It is believed that CM may induce the release 
of the vasoconstrictor molecules endothelin-1 and adenosine 
that may contribute to reduced blood flow and hence lead to 
hypoxic conditions in the renal parenchyma.15 The hypoxic 
conditions thus generated may lead to production of reactive 
oxygen species (ROS) that may have detrimental effects within 
the cells per se.20 The reaction between the ROS superoxide 
anion with nitric oxide will also give rise to the even more 
potent oxidant, peroxynitrite anion. Indeed, the administration 
in vivo of a recombinant manganese superoxide dismutase to 
rats undergoing treatment with the high-osmolar CM diatri-
zoate caused an improvement in the glomerular filtration rate 
(GFR) and a reduction in histological damage.21
Diagnosis of CI-AKI: the necessity 
for novel biomarkers
The diagnosis of CI-AKI is usually based on an absolute 
(≥0.5 mg/dL) or relative (by ≥25%) increase in serum cre-
atinine from baseline.22,23 This is because variation in serum 
creatinine levels after CM application has been interpreted 
as indicating nephrotoxicity by contrast, even though such a 
variation may occur without CM administration.24,25 In some 
cases, contrast-induced AKI is a severe ARF with oliguria 
(<400 mL/24 h), requiring dialysis. In these patients, the 
mortality is high.25,26
It is likely that the renal injury begins immediately 
after CM administration and that sensitive early biomark-
ers could detect the kidney injury very soon,27 and to this 
effect much effort has been made in recent years to identify 
early, specific biomarkers to allow an early diagnosis of AKI 
and hopefully improve the patients’ outcome.28 The term 
biomarker (or biological marker) has been defined as any 
substance, structure, or process that can be measured in the 
body or its products and influence or predict the incidence 
of outcome or disease,29 while the National Institutes of 
Health Biomarkers Definitions Working Group defined a 
biomarker as a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, 
pathogenic processes, or results of therapy.29
A desirable feature of any biomarker is that it is sensitive 
and quantifiable and is able to be analyzed rapidly in order to 
allow timely clinical decisions (interventions) to be made. In 
addition, it would also be beneficial if the biomarker is able 
to give the prognosis and check the efficacy of any therapy. In 
this respect, knowledge of the mechanism or pathophysiology 
of the disease state is important in order to identify biomark-
ers associated with the disease that would offer information 
as to the progress of the disease and efficacy of any therapy 
as evidenced by changes in the levels of the biomarker. The 
urgency for novel biomarkers in renal injury is highlighted 
when one considers that for a measurable change in serum 
creatinine to be significant it is possible that 50% of the 
nephrons have already been injured.30
The studied biomarkers may be an expression of kid-
ney dysfunction, ie, a change in glomerular filtration (eg, 
serum creatinine, Cys-C, and microalbumin) or the result of 
impaired tubular function (eg, N-acetyl-β-d-glucosaminidase 
[NAG]) or upregulated proteins (eg, kidney injury molecule-1 
[KIM-1], neutrophil gelatinase-associated lipocalin [NGAL], 
and IL-18) resulting from renal injury. Figure 1 shows the 
sites of origin of some of these potential biomarkers within 
the nephron of the kidney.
The characteristics of an ideal biomarker have been cited 
by many authors,31–33 and a list of these is given in Table 1.
Since the clinical features and the management of CI-
AKI are the same as those for AKI due to other causes,34,35 
the biomarkers studied to predict an early diagnosis of other 
types of AKI can also be used to predict CI-AKI. We have 
listed those biomarkers of AKI for which at least some data 
are available with regard to their application to CI-AKI.
Creatinine
In the worldwide literature, the renal function is usually evalu-
ated either by measuring serum creatinine or better still by 
utilizing estimated GFR (calculated GFR from the creatinine 
clearance: Modification of Diet in Renal Disease formula,25,36 
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation,37 or Cockcroft–Gault formula38).
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According to some authors,39 serum creatinine is not 
an adequate marker of renal function. The reasons for this 
concern are as follows: 1) Variation in its production from 
muscles and hence it may vary with age, sex, race, and 
weight, which affect muscle mass. Thus, daily changes in 
serum creatinine poorly reflect changes in kidney function 
in patients with AKI. 2) Creatinine undergoes secretion by 
renal tubular epithelium. 3) Altered metabolism of creatinine 
in AKI because severely ill patients are hypercatabolic. 4) 
Dilution of creatinine during volume overload that may be 
present in patients with AKI. 5) There are drugs that alter 
the secretion of creatinine by renal tubules. 6) Creatinine is 
both a late and indirect reflection of kidney damage. 7) Timed 
collection of urine is cumbersome and not accurate.32,40,41
Blood urea nitrogen (BUN) has also been used to diagnose 
AKI and, like serum creatinine, is not an ideal marker of 
kidney injury, its levels being dependent on nonrenal factors 
that are independent of kidney function.42
Cystatin C
The increase in serum creatinine after exposure to CM that 
leads to AKI is delayed, usually achieving a maximum level 
at 2–5 days after contrast exposure. Thus, the use of another 
marker of glomerular filtration has been suggested, namely 
cystatin C (Cys-C).
Cys-C (a 13 kDa protein) is present in all nucleated cells. 
It is filtered by glomeruli and then metabolized in proximal 
renal tubule cells following Megalin-mediated endocytosis.43 
CM causes direct toxic effects to
tubule cells: cell membrane
damage, apoptosis, inflammation,
DNA damage, ROS production
Injured proximal tubule cells release:
Injured distal tubule cells release:
Injured collecting ducts release:
–NGAL
CM toxic effects to endothelial cells
of DVR: vasoconstriction of vessels
leading to RIS production and
damage to nephron
ONOO–
–NAG
–IL-18
–IGFBP7
–TIMP-2
–NGAL
–pi-GST
–Cys-C
–RBP
–Microalbumin
–KIM-1
–NGAL
–IL-18
–L-FABP
–TIMP-2
–IGFBP7
–β2M
–Enzymes (α-GST, GGT, AP)
O2
⋅–
Figure 1 Illustration of toxicity caused by CM in the nephron and sites of origin of biomarkers.
Note: RIS: superoxide (O
2
⋅−) and peroxynitrite (ONOO-).
Abbreviations: CM, contrast media; RIS, reactive inflammatory species; ROS, reactive oxygen species; IL-18, interleukin-18; IGFBP7, insulin-like growth factor-binding 
protein 7; TIMP-2, tissue inhibitor of metalloproteinases-2; NGAL, neutrophil gelatinase-associated lipocalin; π-GST, pi-glutathione S-transferase; NAG, N-acetyl-β-d-
glucosaminidase; Cys-C, cystatin C; β2M, β2-microglobulin; RBP, retinol-binding protein; KIM-1, kidney injury molecule-1; L-FABP, L-type fatty acid-binding protein; α-GST, 
alpha-glutathione S-transferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; DVR, descending vasa recta.
Table 1 Desirable characteristics of potential biomarkers of 
CI-AKI
Easy and simple to measure and be consistent in repetitive measurements
Amenable to sensitive measurement
Provide rapid results that are specific to the injury
Identify source of injury
Allow diagnosis of AKI due to CM, differentiating it from prerenal 
azotemia and CKD
Able to predict or at least estimate timing of onset of CI-AKI
Offer an indication of the severity of injury and to distinguish between 
normal and abnormal functions
Predict outcome of renal injury with respect to recovery/requirement of 
dialysis/mortality
Allow early clinical intervention if necessary and monitoring of the effect 
of the intervention
To be cost effective
To be measurable in biological fluids that can be easily obtained
Abbreviations: CI-AKI, contrast-induced acute kidney injury; CM, contrast media; 
CKD, chronic kidney disease.
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Unlike creatinine, Cys-C is not secreted in the urine by renal 
tubules. Its production occurs at a constant rate. Thus, its 
serum concentration is determined by glomerular filtration.
Cys-C is distributed in the extracellular fluid volume,44 
while creatinine is distributed in the total body water,45 a 
volume which is three times larger. Thus, serum Cys-C rises 
more rapidly than serum creatinine when GFR decreases. The 
shorter t
1/2
 (half-life) of Cys-C explains the earlier change 
in its serum level compared to serum creatinine.46 Thus, 
serum Cys-C is better than serum creatinine as an indicator 
of GFR.47 Since Cys-C is not secreted by renal tubules, its 
appearance in the urine is attributed to AKI.
Briguori et al48 have demonstrated that a rise in serum 
Cys-C of <10% at 24 hours will exclude CI-AKI, while a 
rise ≥10% at 24 hours will be an independent predictor of 
1-year major adverse events, including death and dialysis.
When AKI occurs, the reduced GFR will cause a rise in 
serum Cys-C, taking place much earlier than the increase in 
serum creatinine. In CI-AKI, serum Cys-C has been shown to 
peak as early as 24 hours after radiocontrast administration, 
thereby allowing detection of even small changes in GFR.49–52
Herget-Rosenthal et al53 have determined daily serum 
creatinine and serum Cys-C in 85 patients at high risk to 
develop AKI; 44 patients developed AKI and 41 served as 
controls. The authors concluded that serum Cys-C is a use-
ful marker of AKI and may detect AKI 1–2 days earlier than 
serum creatinine.
It should be noted that both Cys-C and albumin are 
reabsorbed by Megalin-mediated endocytosis in the renal 
proximal tubule.43,54 This means that albuminuria inhibits 
the renal tubular reabsorption of Cys-C, thereby causing 
its urinary excretion.55 Thus, serum Cys-C cannot be used 
as a marker of GFR in nephrotic syndrome. Moreover, the 
analytic evaluation of Cys-C is modified by many associated 
pathologic conditions.32
The cellular injury in the renal proximal tubules will 
cause the appearance of Cys-C in the urine much earlier than 
the occurrence of histologic changes in proximal tubular 
epithelium. When compared with serum Cys-C, urine Cys-C 
appears to be an earlier biomarker of AKI.32
Microalbumin
The term microalbumin indicates the urinary albumin in 
a concentration that is below the threshold of detection of 
albumin by conventional urinary dipstick. Its value ranges 
between 30 mg/L and 300 mg/L. While microalbuminuria 
is believed to be an important marker of alteration of glo-
merular structure and function,56 in vivo rat studies have 
suggested that albuminuria may result from failure of 
proximal tubule cells to retrieve the protein by endocytosis 
during renal injury.57 Microalbuminuria has been utilized 
as a biomarker to investigate attenuation of CI-AKI by 
N-acetylcysteine.58
The occurrence of albuminuria has been shown to precede 
the increase of urinary NAG and serum creatinine.59
A drawback of urine albumin, as marker of AKI, is its 
presence also in chronic renal failure.
N-Acetyl-b-d-glucosaminidase
NAG is a lysosomal enzyme (>130 kDa) that is produced by 
the cells of renal proximal tubules. In healthy subjects, NAG 
is present in the urine in small amounts.
Because of its large molecular weight, NAG cannot be 
filtered by glomeruli: thus, only renal tubule disruption leads 
to its increase in the urine.60
Urinary NAG is increased when the renal proximal tubu-
lar cells are damaged in AKI.61 It has been demonstrated that 
this increase takes place in AKI 12 hours to 4 days earlier than 
the rise in serum creatinine.62 The very high urinary NAG in 
AKI is correlated with poor prognosis.63
Increased urinary excretion of NAG may also be the result 
of increased lysosomal activity without cell disruption.60
Ren et al64 have studied 590 patients who underwent 
percutaneous coronary angiography for acute coronary 
syndromes or stable angina. Urinary NAG, osmolality, and 
serum creatinine were measured before and 1 day, 2 days, and 
6 days after a low-osmolality nonionic radiocontrast agent 
injection. CI-AKI occurred in 33 patients. In these patients, 
urinary NAG and serum creatinine, on days 1 and 2 after 
the radiocontrast injection, were significantly higher than at 
baseline and when compared with patients without CI-AKI. 
Urinary NAG levels peaked earlier and increased much more 
than those of serum creatinine. The authors concluded that 
NAG may be used as early biomarker of CI-AKI in patients 
undergoing coronary angiography and/or therapeutic percu-
taneous coronary intervention (PCI).
Urinary KIM-1
KIM-1 is a phosphatidylserine receptor that when expressed 
in epithelial cells enables them to recognize and phagocytose 
dead cells that are present in the stressed kidney.65 It has been 
found that the ectodomain of KIM-1 is shed into the urine 
of humans after proximal tubule ischemic or toxic injury. 
In normal subjects, KIM-1 is undetectable in the urine.66,67 
Han et al68 demonstrated that urinary KIM-1 is much more 
elevated in ischemic acute tubular necrosis than in CI-AKI.
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Following a renal tubular injury, it is upregulated and 
delivered into the extracellular space and into the urine.67,69
The use of urinary KIM-1 as a biomarker of AKI is based 
on the fact that there is no KIM-1 expression in the kidneys 
of healthy subjects, and on its upregulation in the apical cell 
membrane of tubules during AKI.67
Vijayasimha et al70 have carried out a study to evaluate 
whether KIM-1 allows the identification of CI-AKI earlier 
than the rise in serum creatinine. The study involved 100 
consecutive patients with normal serum creatinine undergo-
ing angiographic procedure. Urinary KIM-1 was assessed at 
4 hours, 8 hours, and 24 hours after the angiographic proce-
dure, while serum creatinine was measured at basal, 24 hours, 
and 48 hours after the procedure. CI-AKI occurred in 12% 
of the patients. A significant increase in urinary KIM-1 was 
observed after 24 hours of coronary angiography (using 
iodixanol or iopromide), while there were no changes in 
estimated GFR up to 48 hours after the angiography. Studies 
on urinary KIM-1 have also been performed in cases of AKI 
due to causes other than CM.
It has been demonstrated that urinary KIM-1 predicts 
AKI71 much more effectively than NGAL in subjects who 
underwent cardiac surgery.72
Sabbisetti et al73 have demonstrated that in surgical 
patients with AKI, plasma KIM-1 was higher than in patients 
without AKI (area under the curve [AUC] 0.96).
Liangos et al74 have shown that urinary KIM-1 and urinary 
NAG did predict adverse prognosis in 201 patients with AKI 
due to different causes.
Jost et al75 using a rat model for age and diabetes-related 
renal impairment found a significant increase in KIM-1 tran-
script levels (measured by quantitative reverse transcription 
polymerase chain reaction) 24 hours after administration of 
the iso-osmolar CM iodixanol.
KIM-1 may be detected by conventional enzyme-linked 
immunosorbent assay (ELISA), and a more sensitive modi-
fication of this technique was developed that requires less 
sample volume.74
Neutrophil gelatinase-associated 
lipocalin
NGAL is a 25 kDa protein associated with human neutrophil 
gelatinase that belongs to the superfamily of the lipocalins.76
The homodimeric form of NGAL is produced by neu-
trophils. But the monomeric (mainly) and the heterodimeric 
forms are the prevalent forms produced by tubules.77
The concentration of NGAL in normal subjects is 
20 ng/mL, both in the serum and in the urine. NGAL is 
 filtered by glomeruli and then reabsorbed by proximal tubules 
where it is partly degraded by megalin and partly excreted in 
the urine. In patients with albuminuria, there is an increase 
in its excretion even without tubular cell damage.
Following renal tubular cell damage, NGAL is released 
into the plasma and the urine; this causes a rise in its plasma 
and urine concentration, much earlier than the increase in 
serum concentration of creatinine.32 Thus, NGAL has the 
potential to act as a powerful and independent predictor of 
AKI.78–81
Many clinical studies and reviews are reported in the 
literature concerning the potential role of NGAL as a reli-
able diagnostic and prognostic biomarker of AKI, since its 
serum and urinary levels increase earlier and show a bet-
ter sensitivity than serum creatinine. Some authors stated 
the plasma NGAL level to be less specific than its urinary 
concentration.66,80
Mishra et al78 have demonstrated that NGAL is a good 
biomarker of AKI in children undergoing cardiopulmonary 
bypass. AKI occurred in 20 out of 71 children, while serum 
creatinine was increased only 1–3 days after the procedure, 
urinary NGAL rose from 1.6 µg/L at baseline to 147 µg/L and 
serum NGAL increased from 3.2 µg/L at baseline to 61 µg/L 
only 2 hours after the cardiopulmonary bypass. Similar results 
have been obtained by other authors.82–86
Wagener et al87 studied 81 adult patients undergoing 
cardiac surgery at Columbia University Medical Center of 
New York; 16 (20%) developed postoperative AKI. Patients 
who developed AKI had significantly higher peak postopera-
tive urinary NGAL (5,994±7,616 ng/mL, n=16) compared 
with patients who did not develop AKI (1,760±3,527 ng/mL, 
n=65; P=0.0014).
Haase-Fielitz et al,88–90 Fadel et al,91 and Krawczeski et al92 
have found similar results in a prospective study of adult 
cardiac surgery patients.
In studies performed in critically ill patients with septic 
shock, Nickolas et al93 found urinary NGAL to predict AKI 
with an AUC of 0.95.
Martensson et al41,94 studied 65 patients admitted to the 
general intensive care unit (ICU) to evaluate the impact 
of inflammation/sepsis on the concentrations of NGAL in 
plasma and urine in adult ICU patients in order to obtain 
an early detection of AKI in patients with septic shock; 27 
patients had systemic inflammatory response syndrome, 
severe sepsis, or septic shock without AKI and 18 patients 
had septic shock and concomitant AKI. Plasma NGAL was 
raised in patients with systemic inflammatory response syn-
drome, severe sepsis, and septic shock and, according to the 
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authors, should be used with caution as a marker of AKI in 
ICU patients with septic shock. The urinary NGAL is more 
useful in predicting AKI, as its levels are normal in septic 
patients who do not have AKI. Similar results were reported 
by Constantin et al95 and, in children, by Wheeler et al.96
Studies have also been performed in transplanted patients 
to figure out whether NGAL may be a biomarker of renal 
dysfunction after transplantation.
Niemann et al97 have evaluated the possibility of using 
NGAL as a marker of early renal injury in patients under-
going liver transplantation. Serum NGAL increased only 
2 hours after transplantation and predicted AKI in all patients.
Li et al98 investigated whether NGAL and L-FABP 
 (liver-type fatty acid binding protein) could be good markers 
for an early diagnosis of AKI in liver  transplanted patients. 
The two markers were detected in the urine of 25 patients 
2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 
72 hours, and 120 hours after the hepatic transplantation. 
Urinary NGAL levels were only slightly elevated at 2 hours 
in the transplanted subjects who were not affected by AKI 
while it rose and stayed high from 2 hours to 6 hours in the 
patients with AKI.
It has been demonstrated that NGAL is also an early, 
sensitive, and predictive biomarker of AKI induced by some 
nephrotoxic drugs.99–101
Parikh et al102 evaluated urinary NGAL and IL-18 in 
renal transplanted patients (who received the kidney from 
cadaver donor) in order to assess whether they can be early 
biomarkers for delayed function of the transplanted organ 
because of tubule cell injury. In patients who had delayed 
graft function, peak posttransplant serum creatinine requir-
ing dialysis occurred at days 2–4 after transplantation, while 
urine NGAL and IL-18 on day 0 were already higher than in 
recipients of living donor kidneys or deceased donor kidneys 
with prompt graft function (P<0.0001).
In a prospective, multicenter, observational cohort study 
of deceased donor kidney transplant patients to evaluate 
whether urinary NGAL, IL-18, and KIM-1 could be used as 
biomarkers for predicting dialysis within 1 week of transplant 
followed by graft recovery, it was concluded that urinary 
NGAL and IL-18, but not KIM-1, predict the future need 
for dialysis.103
Thus, in addition to the usefulness of urinary NGAL in the 
early prediction of the occurrence of AKI, this marker, when 
its levels are high, has been shown to predict poor prognosis 
(dialysis and mortality).86,95,97,104–108
According to Hirsch et al,109 NGAL concentrations 
in urine and plasma are early and powerful independent 
 predictors of CI-AKI in children undergoing elective cardiac 
catheterization with radiocontrast medium.
Similar results were reported by Ling et al,110 Shaker 
et al,111 and others41,112,113 in adult patients undergoing PCI.
Haase et al114 performed a pooled analysis of aggregate 
data from ten prospective observational studies of NGAL, 
including 2,322 critically ill patients; 19.2% of patients had 
increased NGAL without relevant changes in serum cre-
atinine. Thus, they defined “subclinical AKI” when patients 
have increased urinary NGAL while serum creatinine is still 
normal. It remains unclear whether in these cases NGAL is 
an indicator of subclinical AKI or simply a marker of severity 
of illness of these patients.28
In conclusion, NGAL is a good marker of AKI, since its 
increase in the serum and in the urine occurs earlier than the 
rise in serum creatinine.66
Urinary IL-18
IL-18 is a cytokine that belongs to the IL-1 superfamily.
IL-18 is involved in acute ischemic AKI. It is doubled in the 
renal proximal tubules of the kidneys of AKI patients and is pro-
duced from the IL-18 precursor by the action of caspase-1.115,116
Urine levels of IL-18 are increased in acute tubular 
 necrosis but not in prerenal azotemia. It is a sensitive and 
specific biomarker of AKI.117
A meta-analysis of 23 studies involving 4,512 patients 
has demonstrated that urine IL-18 is a good biomarker of 
AKI in patients undergoing cardiac surgery, in patients 
admitted in ICUs, and in coronary care units.118 Parikh et 
al102 evaluated the role of urinary NGAL and IL-18 to pre-
dict delayed graft function in kidney transplanted patients 
from cadaver donors: urinary IL-18 (like urinary NGAL) 
represents an early, predictive biomarker of delayed graft 
function after kidney transplantation.102 Urinary IL-18, like 
urinary NGAL, is an early noninvasive, accurate predictor 
of the need for dialysis within the first week after kidney 
transplantation.103
Parikh et al82 have evaluated whether IL-18 is a predic-
tive biomarker of AKI after cardiopulmonary bypass, as they 
have shown for urinary NGAL.78 Their study was performed 
using 20 patients who developed AKI and 35 controls who 
did not develop AKI after cardiopulmonary bypass. Using 
serum creatinine as a marker, AKI was detected 2–3 days 
after the cardiopulmonary bypass. But, when measuring 
levels of urinary IL-18, it was observed that these had already 
increased 4–6 hours after cardiopulmonary bypass, peaking 
at 12 hours, and remaining markedly elevated up to 48 hours 
after cardiopulmonary bypass. The results indicate that IL-18, 
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like NGAL, is an early, predictive biomarker of AKI after 
cardiopulmonary bypass.
The same group119 carried out a case–control study within 
the Acute Respiratory Distress Syndrome (ARDS) Network 
trial to figure out whether urinary IL-18 is an early diagnostic 
marker of AKI. The authors concluded that urinary IL-18 can 
be used for the early diagnosis of AKI and also to predict 
the mortality of patients who have acute respiratory distress 
syndrome and are in the ICU.
The same group120 also carried out a prospective, multi-
center cohort study involving 311 children undergoing surgi-
cal treatment of cardiac lesions. On the basis of their results, 
the authors concluded that urinary IL-18 and urinary NGAL, 
but not plasma NGAL, are associated with the  subsequent 
AKI and poor outcomes among children undergoing cardiac 
surgery.
But different results were obtained by Siew et al,121 
who prospectively evaluated the capacity of urinary IL-18, 
measured within 24 hours of admission, to predict AKI, 
death, and receipt of acute dialysis in a large mixed adult 
population of 451 ICU patients (86 developed AKI within 
48 hours of enrollment). On the basis of their results, the 
authors concluded that urine IL-18 is not a good marker 
of AKI.
In addition, studies of AKI caused by CM have yielded 
conflicting results with regard to IL-18 as a biomarker of 
injury.
He et al122 carried out a study on 180 patients who under-
went coronary interventional procedures at the Department 
of Cardiology. Urine IL-18 levels were found to be increased 
in the CI-AKI patients 6–12 hours after the CM injection, 
compared with those in the non-CI-AKI patients (P<0.01). 
The authors concluded that urine IL-18 is a good marker of 
CI-AKI.
Ling et al110 have reached the same conclusion: urinary 
IL-18, like NGAL, is quite effective, in allowing an early 
diagnosis of CI-AKI compared with serum creatinine 
(P<0.05).
Different results have been obtained by Bulent Gul et 
al,123 who carried out a case–control study using a cohort of 
157 patients admitted to hospital for elective PCI for stable 
angina. Fifteen patients (9.5%) had CI-AKI. No statistically 
significant difference was observed in urinary IL-18 in the 15 
cases of CI-AKI compared with non CI-AKI patients; neither 
was a significant difference detected between urinary IL-18 
before and after PCI. The authors concluded that urine IL-18 
cannot be used as a marker of CI-AKI following intravascular 
injection of iodinated CM.
Hayashi and Izawa66 have also disputed the use of IL-18 
as a reliable biomarker of CI-AKI.
Liver-type Fatty Acid-Binding 
Protein
The FABP family of proteins consists of 15 kDa proteins 
present in the cytoplasm of tissues with fatty acid metabolism, 
serving as intracellular lipid chaperones that transport lipids 
within the cell. In proximal tubular cells, FABPs transport free 
fatty acids to the mitochondria or peroxisomes where they are 
metabolized by β-oxidation.124 Two types of FABP are found in 
the kidney: liver-type (L-) FABP, located in the renal proximal 
convoluted and straight tubules (it can also be reabsorbed from 
the glomerular filtrate via megalin, a multiligand proximal 
tubule endocytic receptor), and heart type (H-) FABP, located 
in the renal distal tubules. In normal subjects, L-FABP is not 
detected in the urine. Kamijo et al, using a transgenic mouse 
model expressing human L-FABP, correlated the levels of uri-
nary L-FABP with stress suffered by the proximal tubules and 
also presented clinical data correlating urinary L-FABP with 
severity of tubulointerstitial injury.125 Under normal conditions, 
L-FABP is present in the lysosomal compartment of the renal 
proximal convoluted and straight tubules.52
Experimental studies have demonstrated that increased 
urine L-FABP is a good marker of ischemic AKI.126 Thus, 
Negishi et al127 have carried out a study to evaluate whether 
urinary L-FABP could be used to monitor histological injury 
in AKI induced by cis-platinum injection and ischemia reper-
fusion. AKI of different severity was induced by cis-platinum 
injection and ischemia time in human L-FABP transgenic 
mice. Renal histological injury scores increased with both 
cis-platinum dose and ischemic time. In the AKI induced 
by cis-platinum, urinary L-FABP increased exponentially as 
early as 2 hours after toxin injection, while BUN increased 
only at 48 hours. In the AKI induced by ischemia, BUN levels 
increased only in the 30-minute ischemia group followed by 
24 hours of reperfusion, while urinary L-FABP increased 
>100-fold, even in the 5 minute ischemia group followed 
by 1 hour of reperfusion. On the basis of their results, the 
authors concluded that urinary L-FABP is the best marker 
for early detection of histological and functional insults in 
ischemic and nephrotoxin-induced AKI.
L-FABP is a good marker of AKI in patients treated with 
cisplatin,128 in patients with septic shock,99,129 and in subjects 
receiving CM.130
Clinical studies have demonstrated that urinary L-FABP 
was elevated a few hours after cardiopulmonary bypass 
surgery, appearing as an independent risk indicator of AKI 
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 post-cardiac surgery, suggesting it to be a sensitive, predic-
tive, and early  biomarker of AKI after cardiac surgery.128,131 
Similar results have been observed in patients admitted to 
the ICU with sepsis.132
Yamamoto et al126 have studied the potential role of 
L-FABP as a biomarker of renal ischemia following human 
kidney transplantation from living-related donors. Urinary 
L-FABP was measured in the first urine produced from 12 
kidney transplant recipients immediately after reperfusion 
of the transplanted organ. At the same time, intravital video 
analysis of peritubular capillary blood flow was performed. 
The authors found a significant direct correlation between 
urinary L-FABP and both peritubular capillary blood flow 
and the ischemic time of the transplanted kidney (P<0.0001). 
These data showing an increase in urinary L-FABP after 
ischemic–reperfusion injury (IRI) suggest that L-FABP is a 
biomarker of AKI.
L-FABP may be useful when it has to be decided to 
perform either a combined kidney–liver transplantation or 
a liver transplantation alone in patients with liver disease. If 
urinary L-FABP is present, the kidneys are damaged, sug-
gesting a combined kidney–liver transplantation. Under such 
condition, serum creatinine, in fact, does not help since it 
does not increase, despite there being damage to the kidney.133
Urinary levels of the L-FABP have been shown to 
increase in patients who develop AKI after exposure to IV 
CM.133–137
Bachorzewska-Gajewska et al112 studied 25 patients with 
normal serum creatinine who underwent PCI for unstable 
angina: urinary L-FABP increased significantly, like urinary 
NGAL, after 4 hours and remained elevated up to 48 hours.
The observations of a study of 91 hospitalized patients 
performed by Ferguson et al138 are also worthy of note. These 
authors demonstrated that urinary L-FABP is not only a good 
diagnostic marker of AKI (five patients had CI-AKI) but has 
also prognostic significance, since its urinary levels were 
significantly higher in patients with a poor outcome, defined 
as the requirement for renal replacement therapy.
However, some authors deny any predictive value of 
L-FABP for CI-AKI.66 In addition, Li et al,98 who studied 
the behavior of NGAL and L-FABP in liver transplant recipi-
ents, concluded that L-FABP is not a marker of AKI in liver 
transplant recipients.
Netrins
Netrins belong to the laminin-related family. There are 
three secreted netrins (netrin-1, -3, and -4).139 Netrins 
are located in the peritubular capillaries of the kidneys. 
During IRI, netrin-1 is highly concentrated within the 
renal tubular epithelial cells.140 In various mice models 
of AKI (IRI and toxin-induced injury), levels of netrin-1 
were found to be induced in renal tubules, and its urinary 
levels dramatically increased. Urinary netrin-1 increased 
early (within a few hours) and dramatically and returned 
to baseline within 24 hours, and in some cases preceded 
BUN and creatinine by 24 hours.141 It can be measured 
in urine by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, Western blots, and commercially  available 
ELISA kits.
Midkine
Midkine (MK) is a 13 kDa growth factor with various 
biological roles, including inflammation;37 it regulates cell 
growth and survival, migration, and antiapoptotic activity in 
nephrogenesis and development.142
In the mouse kidneys, MK expression is found in the 
proximal tubular cells where it is tentatively believed to 
play a role in promoting the survival of these cells143 and 
is also present in endothelial cells.144 In a mouse model of 
IRI, it was found that MK levels were increased threefold 
in proximal tubular cells, leading to neutrophil recruitment 
and resulting in an inflammatory reaction and tubuloint-
erstitial damage.143 It was believed that superoxide anions 
produced during the IRI procedure led to the upregula-
tion of MK, and it is feasible that MK expression could 
be altered during CI-AKI. Malyszko et al145 investigated 
whether MK could represent an early biomarker of CI-
AKI in 89 patients with normal serum creatinine levels, 
who underwent PCI for angina, using the iso-osmolar CM 
iodixanol. Serum MK was evaluated before and 2 hours, 
4 hours, 8 hours, 24 hours, and 48 hours after the adminis-
tration of the radiocontrast medium; serum creatinine was 
assessed before and 24 hours and 48 hours after CM injec-
tion. CI-AKI – defined as an increase in serum creatinine 
by >25% of the baseline 48 hours after PCI – occurred in 
10% of the patients. In these patients with CI-AKI, the 
authors found a significant rise in serum MK after only 
2 hours (P<0.001 compared to the baseline values); MK 
remained significantly higher 4 hours after the administra-
tion of CM to return to the baseline values after 24 hours. 
In this same study, NGAL levels were significantly higher 
at 2 hours (serum NGAL) or 4 hours (urinary NGAL) after 
PCI. Cys-C was higher at 8 hours and 24 hours after PCI 
in patients with CI-AKI.
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Cell cycle arrest markers
A recent study by Kashani et al146 identified the urine insulin-
like growth factor-binding protein 7 (IGFBP7) and the tissue 
inhibitor of metalloproteinases-2 (TIMP-2), as both involved 
in cell cycle arrest.147,148 Kashani et al146 carried out a prospec-
tive, multicenter investigation in which the two new biomark-
ers of AKI – IGFBP7 and TIMP-2 – were found in the urine of 
adult patients at high risk of AKI. The study had two phases: 
discovery phase and validation phase. In the discovery phase, 
blood and urine samples were obtained from the patients of 
three cohorts (all three from ICUs, after which the data were 
then pooled) with the purpose of identifying new biomark-
ers of AKI among 340 proteins. In the validation phase, a 
fourth cohort was called Sapphire study146 and was made up 
of 35 ICUs (total of 744 subjects) in North America (460 
subjects) and Europe (284 subjects). AKI occurred in 14% of 
Sapphire subjects. The two biomarkers IGFBP7 and TIMP-2 
from discovery were validated. Urine IGFBP7 and TIMP-2 
together demonstrated an AUC of 0.80, much greater than 
that of all known markers of AKI, none of which achieved 
an AUC >0.72. The authors conclude that both are excellent 
biomarkers of AKI and provide additional information over 
other clinical variables. Cell cycle arrest may result as a 
consequence of cellular damage, in particular DNA damage, 
thus preventing the cell from entering cell division. Cellular 
DNA damage by CM has been reported;17 and therefore, it 
is feasible that the CM may upregulate these cell cycle arrest 
markers in renal tubule cells and may be detected in urine 
after CM-induced renal injury.
It should be noted that while some other authors have 
confirmed that TIMP-2 and IGFBP7 are good markers of 
AKI,149–153 other authors have denied their usefulness as 
markers of AKI.154
Alpha-glutathione S-transferase and 
pi-glutathione S-transferase
These two enzymes are present in many organs, kidneys 
included. They cannot be found in the urine of normal sub-
jects. Following renal injury, alpha-glutathione S-transferase 
(α-GST) is detected in the tubular proximal cells, pi-gluta-
thione S-transferase (π-GST) in the distal tubular cells.60
In the prospective study of Westhuyzen et al,62 urine 
samples from 26 patients who were admitted to the ICU were 
collected twice daily for up to 7 days. Four patients (15.4%) 
developed AKI (ie, at least 50% increase in serum creatinine 
that occurred between 12 hours and 4 days after the admis-
sion). The two tubular enzymes, α-GST and π-GST, in the 
urine indexed to urine creatinine gave an AUC of 0.893 and 
0.929, respectively. The authors concluded that urinary tubular 
enzymes are useful in predicting AKI. However, in an in vivo 
study using various rat models of hypertension, diabetes, 
and nephropathy,155 no significant increase in α-GST was 
observed after IV administration with the low-osmolar CM 
(LOCM) iohexol.
Gamma-glutamyl transpeptidase 
and alkaline phosphatase
Gamma-glutamyl transpeptidase (GGT) and alkaline phos-
phatase are two enzymes on the brush border of the renal 
proximal tubules, which appear in the urine when damage 
of the brush border occurs.60
Westhuyzen et al62 have studied four cases of AKI out 
of 26 consecutive patients who were admitted to the ICU. 
The markers GGT, alkaline phosphatase, NAG, α-GST, and 
π-GST were increased in the subjects with AKI when com-
pared with patients who did not develop AKI (P<0.05), on 
admission and they remained elevated at 24 hours. The levels 
of GGT in the urine were very high in 22 patients injected 
with the high-osmolar CM diatrizoate and in 12 patients 
with the LOCM iohexol, 24 hours after CM administration, 
while there was no increase in serum creatinine.156 A more 
recent study set out to investigate the predictive value of GGT 
for risk of CI-AKI in patients who underwent primary PCI. 
Patients were divided into three groups depending on the 
levels of GGT measured in the patients on admission (group 
1: GGT <19 U/L, group 2: GGT 19–33 U/L, and group 3: 
GGT >33 U/L). The study found that CIN incidence was 
significantly higher in group 3 and concluded that GGT was 
a significant predictor of CI-AKI.157
b2-Microglobulinβ
2
-Microglobulin (β2M) is an 11.8 kDa protein that is filtered 
by glomeruli and reabsorbed by the renal proximal tubules.158 
While low levels of β2M are found in urine and serum of 
normal subjects, they rise after renal injury due to decreased 
reabsorbance by the damaged tubules.
In a study of 68 cases of multiple myeloma undergoing 
computerized tomography scan, 12 patients who had received 
an LOCM suffered from CI-AKI within 7 days.159 It was 
observed that β2M levels correlated with the occurrence 
of CI-AKI, but other parameters used in the study, namely 
albumin level and BUN–creatinine ratio, did not.
Retinol-binding protein
Retinol-binding protein is a 21 kDa protein that is filtered by 
glomeruli and is reabsorbed by proximal tubules. It has been 
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shown to be a good marker of AKI.160 It has been used as a 
marker in assessing prophylactic treatments for CI-AKI.161
MicroRNA molecules as potential 
biomarkers of CI-AKI
MicroRNA (miRNA) molecules are involved in proliferation, 
differentiation, and death of cells as well as in inflamma-
tion. It is reasonable to suggest therefore that they may be 
implicated in the pathogenesis of CI-AKI. The identifica-
tion of such molecules will enable a further understanding 
of the pathogenesis of kidney injury as well as serving as 
biomarkers of the injury. One advantage of using miRNAs 
as biomarkers is their stability in serum, urine, and saliva,162 
with some reports suggesting that they may be stable in urine 
samples after several freeze–thaw cycles and even up to 
24 hours at room temperature,163 while others have reported a 
significant level of viability of miRNA molecules after 5 days 
of storage at 4°C.164 A disadvantage is that miRNA levels 
in body fluids are low and require sensitive and specialized 
tools for analysis.
The miR-21 has been extensively studied and found to 
play a role in cell proliferation and downregulation of apop-
tosis after renal IRI and inflammation.165–168 Serum and urine 
levels of miR-21 also predicted the progression of AKI in 
cardiac surgery patients.169 In an in vivo mouse model study, 
renal ischemia reperfusion caused the increase of several 
miRNA molecules in plasma and kidneys when compared 
with sham-treated mice, at 3 hours, 6 hours and 24 hours 
following the ischemic injury.170 These molecules were cor-
related with plasma creatinine and histological observations 
of tubular degeneration and necrosis. In particular, the mRNA 
targets of one of these molecules, miR-1897-3p, included 
that of  nuclear casein kinase and cyclin-dependent kinase 
substrate 1. Targets of nuclear casein kinase and cyclin-
dependent kinase substrate 1 have been implicated in renal 
injury, inflammation, and apoptosis.170 Another study utilized 
serum samples from normal subjects and patients with AKI; 
miRNA molecules could be considered as markers of AKI.171 
Notably, several of the miRNA molecules had already been 
associated with kidney injury: in proximal tubule adhe-
sion and trafficking during IRI (miR-127), in an in vivo 
mouse model of IRI and in patients with immunoglobulin 
A nephropathy (miR-146a), and in progression of chronic 
kidney disease (miR-29a). In addition, several of the miRNA 
molecules could also be correlated with AKI severity accord-
ing to the Acute Kidney Injury Network classification.171 Two 
groups have found several miRNAs whose serum levels were 
increased in patients with CI-AKI.172,173 Future aims could 
be directed toward identifying miRNAs that are expressed 
specifically in the kidney174 and to correlate their changes 
with kidney injury due to use of CM.
Metabolomic studies to identify 
biomarkers
Metabolomics may be simply defined as the study and mea-
surement of metabolites present in the cell, tissue, or organism. 
The last few years has seen a number of studies investigating 
changes in metabolites accompanying AKI, especially with 
respect to the use of nephrotoxins such as cisplatin.175,176 
A recent study investigated changes in the metabolic profiles 
in a mouse model of IRI, in which a period of renal ischemia 
was followed by 2 hours to 7 days of  reperfusion,177 using 
gas chromatography/mass  spectrometry and liquid chroma-
tography/mass spectrometry analysis. There were changes in 
metabolites related to energy and purine metabolism as well 
as osmotic regulation and inflammation. Changes in a wide 
range of metabolites may be considered together, giving rise 
to a signature associated with the injury. In this respect, the 
authors reported such signatures of inflammation: changes 
in prostaglandins, increased catabolism of tryptophan via 
the kynurenate pathway, and changes in arginine metabolism, 
which has also been associated with renal failure.178 Of note, 
an increase in the metabolite 3-indoxyl sulfate was observed 
early on during reperfusion, and it could serve as a potential 
biomarker, given that it has also been reported as increasing 
in other models of toxin-induced renal failure.176 In another 
study, changes were noted in urinary metabolites of patients 
undergoing computerized tomography scan  scan and admin-
istered with the LOCM iohexol,179 but the study did not set 
out to associate any of these changes with CI-AKI.
Biomarker measurement and 
quantification
The discovery of novel potential biomarkers brings with 
it fresh challenges for their accurate, rapid, and reproduc-
ible measurements. Nephelometry and turbidometry have 
been used to measure some of these markers (Table 2) and 
improved particle enhanced turbidometric and nephelo-
metric immunoassays have improved analysis in terms of 
reduction in sample volume required and time. The protein 
biomarkers have also been analyzed by the use of ELISA 
and by Western blotting. The traditional ELISA has several 
disadvantages including the fact that only one antigen can be 
detected per assay plate, relatively large volumes of sample 
are required, the need to optimize the volumes of sample 
in order for the protein to be measured within an accepted 
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range, and it may take several hours to obtain a result. An 
advantage however is that it is easy to perform with relatively 
little technical expertise required. Similar disadvantages are 
also inherent with Western blotting, which may take as long 
as the traditional ELISA to yield results, although some com-
panies have developed equipment that can reduce turnaround 
time. Recent advances in multiplex technologies can reduce 
the requirement for sample amount and time for analysis 
while being able to analyze many molecules together.180 
These technologies include the use of micrometer plastic 
beads impregnated with fluorescent dyes and coated with a 
specific antibody to an antigen of interest (biomarker). Many 
sets of these beads with each set having a specific antibody 
to a specific antigen (biomarker) will be combined with the 
biological sample to be tested (urine and serum), followed 
by combining with a mixture of detection antibodies (for 
each biomarker of interest) which have been labeled with a 
reporter dye different from the dyes within the beads. Then, 
the bead biomarker–reporter mixture is analyzed through 
an analytical flow chamber. Another multiplexed assay is 
based upon the standard 96-well microtiter plate, which 
offers the possibility of using preexisting equipment for 
analysis. It should still be noted that reproducibility of data 
is still dependent on the source of antibodies used and may 
be subject to batch-to-batch variation.
MiRNA molecule expression may be studied by micro-
array analysis, real-time polymerase chain reaction, in situ 
hybridization, solution hybridization, and Northern blotting. 
Of these, quantitative reverse transcription polymerase 
chain reaction is the most accurate and sensitive. How-
ever, the analysis of miRNAs can be a challenge and time 
consuming, requiring their isolation from samples and the 
use of specific reagents and analytical instruments. These 
techniques will also require a degree of technical ability. 
Similarly, the study of metabolomics depends on sophisti-
cated equipment such as nuclear magnetic resonance spec-
troscopy and the already mentioned gas chromatography/
mass spectrometry and liquid chromatography/mass spec-
trometry, which also require skilled operators. In addition, 
samples may need to be prepared prior to analysis, which 
will lengthen the procedure, but analysis of metabolites 
may be aided by the existence of public databases such as 
the Human Metabolome Database.
Some ideas of potential treatment/
prevention of CI-AKI
Once CI-AKI has been established, there are limited treatment 
options available. The management of CI-AKI is the same 
as that for AKI due to other causes.5,10,35
What is important is prevention.
The first general rule of prevention is that in any patient 
undergoing any radiographic procedure, the occurrence of 
renal injury should be detected as early as possible, and this 
may be achieved by using several sensitive early biomarkers 
that may include serum creatinine, Cys-C, NGAL, KIM-1, 
IL-18, and L-FABP, and to repeat any preventive measures 
in the few days following the use of CM. This may need to 
be done even though no robust evidence exists to support 
the reliability of any specific biomarker in clinical studies. 
The diagnosis of AKI is even more difficult in the elderly 
because of their clinical conditions favoring the occurrence 
of CI-AKI: dehydration, due to impaired sensation of thirst4 
and tendency to salt depletion following abnormal renal salt 
losses associated with insufficient salt intake and reduction 
in “effective” circulating blood volume, that aggravate renal 
vasoconstriction, thereby predisposing to AKI.26 The effec-
tive circulating blood volume may be defined as the relative 
Table 2 Potential biomarkers of contrast-induced acute kidney 
injury
Biomarker Location in kidney Method of 
detection
Cystatin C (Cys-C) Produced by all 
nucleated cells, filtered 
by glomerulus, and 
reabsorbed by proximal 
tubule cells
Enzyme-linked 
immunosorbent 
assay (ELISA) and 
nephelometric and 
turbidometric assays
Neutrophil 
gelatinase-associated 
lipocalin (NGAL)
Expression upregulated 
in proximal tubule cells 
after renal injury
ELISA, immunoblotting, 
and turbidometric 
assay
N-Acetyl-β-
glucosaminidase 
(NAG)
Proximal tubule 
lysosomal enzyme
ELISA and 
spectrophotometric 
assay
Kidney injury 
molecule-1 (KIM-1)
Upregulated in 
dedifferentiated proximal 
tubule cells
ELISA and 
immunoblotting
L-fatty acid binding 
protein (L-FABP)
Expressed in proximal 
tubule cells
ELISA
Interleukin-18 
(IL-18)
Expressed in distal 
tubule cells; expression 
may be induced in 
proximal tubules
ELISA
Midkine (MK) Expressed in proximal 
tubule cells
ELISA
Retinol-binding 
protein (RBP)
Filtered by the 
glomerulus and 
reabsorbed by the 
proximal tubule cells
ELISA and 
nephelometric assay
β2-Microglobulin 
(β2M)
Filtered by the 
glomerulus and 
reabsorbed by the 
proximal tubule cells
ELISA and 
nephelometric assay
Notes: Particle-enhanced turbidometric and nephelometric immunoassays are 
relatively quick, avoiding the need for sample pretreatment and allowing use of less 
sample. Similarly, the development of bead-based multiplex immunoassays will allow 
the detection of several molecules at the same time compared with conventional ELISA.
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fullness of the arterial tree as determined by cardiac output, 
peripheral vascular resistance, and total blood volume.5 
A reduction in the effective circulating blood volume in the 
elderly may be due to congestive heart failure, compromised 
left ventricle systolic performance, and prolonged hypoten-
sion; under such circumstances, renal vasoconstriction is 
accentuated, thereby making renal ischemia more severe.3,181
Measures to prevent CI-AKI that may be useful for 
physicians include: 1) discontinuation of potentially neph-
rotoxic drugs (aminoglycosides, vancomycin, amphotericin 
B, metformin, and nonsteroidal anti-inflammatory drugs2; 
2) choice of the least nephrotoxic radiocontrast agent 
(iohexol is less nephrotoxic than diatrizoate; iodixanol and 
iopamidol seem the least nephrotoxic agents10; 3) use of the 
lowest dosage possible of CM (some formulas have been 
suggested to calculate the dosage that is least dangerous for 
the kidney182–185; 4) adequate hydration of the patient186,187 
by IV infusion of 0.9% saline at a rate of ~1 mL/kg body 
weight/hr or 154 mEq/L infusion of sodium bicarbonate as 
a bolus of 3 mL/kg bw/hr for 1 hour;188 5) short-duration 
pretreatment with antioxidants, such as N-acetylcysteine 
(an oral dose of 600 mg twice daily the day before and the 
day of procedure10 or an IV dose of 150 mg/kg over half an 
hour before the  procedure or 50 mg/kg administered over 
4 hours;189 6) Nebivolol (5 mg/d for 1 week or 5 mg every 
24 hours for 4 days).190,191
Summary and future perspectives
CI-AKI is a leading cause of hospital-acquired kidney failure 
and no doubt will continue to increase with the increase in use 
of radiological procedures. Serum creatinine is still utilized 
as marker of kidney function, even though it is a late marker 
of renal injury and its measurement may be cumbersome and 
its levels may not reflect kidney damage. Hence, there is an 
urgent need for new markers, and many promising serum and 
urinary biomarkers have been identified that may be able to 
detect CI-AKI prior to the expected rise in serum creatinine, 
including Cys-C, NGAL, KIM-1, IL-18, and L-FABP, and 
may give a diagnosis in hours rather than days. However, there 
are still reports questioning the accuracy and reliability of 
these new biomarkers in the context of AKI, and more studies 
are required to clarify their effectivity. There is certainly a 
need for well-designed, multicenter clinical trials enrolling 
many patients in order to clarify the potential of a particular 
biomarker in different sets of patients (age group: elderly 
adult, adult, child, infant, neonate; and those presenting 
other disease states: diabetes, cardiovascular disease, etc). In 
addition, it may be the case that more biomarkers should be 
quantified in tandem in order to properly evaluate the extent 
of renal injury. In this respect, newer technologies may be 
useful in allowing rapid and accurate measurements of several 
molecules simultaneously, such as the development of bead-
based multiplex immunoassays, and further developments in 
technology will in turn be spurred on by clinical develop-
ments in diagnosis of the disease. We can also look forward 
to other approaches in discovering potential biomarkers such 
as the use of miRNA molecules and metabolomic analyses, 
which may however require sophisticated and expensive 
equipment together with greater technical expertise, but this 
will be outweighed by the potential benefits. The hope for the 
future is that this will allow for more timely and successful 
intervention and lead to improved patient care.
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